Heska Corp (NASDAQ:HSKA) – Equities researchers at Piper Jaffray Companies lifted their FY2019 EPS estimates for Heska in a report released on Tuesday, November 5th. Piper Jaffray Companies analyst W. Quirk now anticipates that the medical research company will post earnings of $0.12 per share for the year, up from their prior estimate of $0.03. Piper Jaffray Companies currently has a “Neutral” rating and a $68.00 target price on the stock. Piper Jaffray Companies also issued estimates for Heska’s Q4 2019 earnings at $0.10 EPS, Q1 2020 earnings at ($0.03) EPS, Q2 2020 earnings at $0.01 EPS, Q3 2020 earnings at $0.13 EPS, Q4 2020 earnings at $0.23 EPS, FY2020 earnings at $0.34 EPS and FY2021 earnings at $0.81 EPS.
Several other research analysts have also recently issued reports on the stock. Raymond James cut shares of Heska from an “outperform” rating to a “market perform” rating in a report on Thursday. They noted that the move was a valuation call. BidaskClub upgraded shares of Heska from a “hold” rating to a “buy” rating in a research report on Thursday, October 31st. Canaccord Genuity reiterated a “buy” rating and issued a $105.00 price target (up previously from $75.00) on shares of Heska in a research report on Wednesday. Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, ValuEngine upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $85.75.
Shares of Heska stock traded up $0.29 during trading hours on Friday, hitting $90.94. The company had a trading volume of 2,932 shares, compared to its average volume of 88,930. The company’s 50-day moving average is $75.36 and its two-hundred day moving average is $76.23. Heska has a twelve month low of $62.47 and a twelve month high of $105.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 8.52 and a quick ratio of 2.05. The company has a market cap of $735.22 million, a P/E ratio of 64.01 and a beta of 1.06.
Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Heska had a net margin of 3.15% and a return on equity of 3.17%. The business had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million.
Several institutional investors and hedge funds have recently made changes to their positions in HSKA. FMR LLC increased its holdings in shares of Heska by 2.0% in the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after purchasing an additional 8,870 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in shares of Heska in the 2nd quarter valued at about $852,000. NJ State Employees Deferred Compensation Plan increased its holdings in shares of Heska by 40.0% in the 2nd quarter. NJ State Employees Deferred Compensation Plan now owns 7,000 shares of the medical research company’s stock valued at $596,000 after purchasing an additional 2,000 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Heska by 2.7% in the 2nd quarter. Arizona State Retirement System now owns 10,821 shares of the medical research company’s stock valued at $922,000 after purchasing an additional 285 shares in the last quarter. Finally, Financial Gravity Wealth Inc. purchased a new position in shares of Heska in the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 92.57% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Further Reading: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.